| Previous Close | 12.25 |
| Open | 12.18 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 12.18 - 12.49 |
| 52 Week Range | 8.30 - 18.00 |
| Volume | |
| Avg. Volume | 115,934 |
| Market Cap | 3.738B |
| Beta (5Y Monthly) | -0.08 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.65 |
| Earnings Date | Nov 20, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.00 |
GlobeNewswireAlvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitis The FDA previously approved SELARSDI 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled syringe for subcutaneous injection in April 2024SELARSDI’s U.S. launch for all indications is expected in Q1 2025 REYKJAVIK, Iceland & PARSIPPANY, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U
- GlobeNewswire
European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT03, a proposed biosimilar candidate to Prolia® and Xgeva® (denosumab). “EMA acceptance marks an important step towards making AVT03 available to patients and caregivers in Europe,” said Joseph McClellan, Chief Scientific Officer of Alvotec
Simply Wall St.High Growth Tech Stocks in the United States to Watch
In the last week, the market has stayed flat while the Materials sector gained 3.1%, and over the past 12 months, it has risen by 32% with earnings forecasted to grow by 15% annually. In this context, identifying high growth tech stocks becomes crucial as they often offer significant potential for capital appreciation in a steadily advancing market.
